Hetero debuts biosimilar of Roche's Avastin in India
Indian generics drugmaker Hetero Group said today it has launched a biosimilar of bevacizumab, the active ingredient of Swiss pharma giant Roche’s (ROG: SXI) blockbuster cancer drug Avastin, in India for the treatment of metastatic colorectal cancer (mCRC).
The product has been approved by Drug Controller General of India (DCGI) and has been recommended as a first-line treatment for mCRC. The product will be made available to patients in a single dose vial with two strengths, 100mg and 400mg. It will be marketed and distributed by Hetero Healthcare, a group company of Hetero under the brand name Cizumab.
"Roche has filed a lawsuit to block the launch of Hetero's biosimilar bevacizumab before the Honourable High Court. However the High Court has not given any injunction order and as such the launch is not prohibited," a Hetero spokesperson told Business Today. Bevacizumab has received the required approvals from the regulatory authority to launch the product, he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze